Compare Amphastar Pharmaceuticals Inc (AMPH) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

PALL (abrdn Physical Palladium Shares ETF) trades at $23.07, up 1.63% with bearish technical signals from moving averages but neutral oscillators. The ETF recently underwent a 5-for-1 stock split effective May 18, 2026. Financial ratios are unavailable, but palladium's 47% price decline from January 2026 highs has drawn attention as a potential catch-up trade amid broader precious metals strength.

The outlook hinges on palladium's supply-demand dynamics, with Seeking Alpha highlighting a buying opportunity at current levels due to industrial demand and supply risks. Key risks include Federal Reserve policy impacts and commodity volatility. Analyst sentiment is cautiously optimistic, viewing the price weakness as a potential entry point for exposure to palladium's recovery prospects.